Unknown

Dataset Information

0

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.


ABSTRACT: Gene expression profiles have been associated with clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-containing chemotherapy. Using Affymetrix HU133A microarrays, we analyzed the lymphoma transcriptional profile of 30 patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and 23 patients treated with rituximab (R)-CHOP in the Groupe d'Etude des Lymphomes de l'Adulte clinical centers. We used this data set to select transcripts showing an association with progression-free survival in all patients or showing a differential effect in the two treatment groups. We performed real-time quantitative reverse transcription-PCR in the 23 R-CHOP samples of the screening set and an additional 44 R-CHOP samples set to evaluate the prognostic significance of these transcripts. In these 67 patients, the level of expression of 16 genes and the cell-of-origin classification were significantly associated with overall survival, independently of the International Prognostic Index. A multivariate model comprising four genes of the cell-of-origin signature (LMO2, MME, LPP and FOXP1) and two genes related to immune response, identified for their differential effects in R-CHOP patients (APOBEC3G and RAB33A), demonstrated a high predictive efficiency in this set of patients, suggesting that both features affect outcome in DLBCL patients receiving immunochemotherapy.

SUBMITTER: Jais JP 

PROVIDER: S-EPMC2675107 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.

Jais J-P JP   Haioun C C   Molina T J TJ   Rickman D S DS   de Reynies A A   Berger F F   Gisselbrecht C C   Brière J J   Reyes F F   Gaulard P P   Feugier P P   Labouyrie E E   Tilly H H   Bastard C C   Coiffier B B   Salles G G   Leroy K K  

Leukemia 20080710 10


Gene expression profiles have been associated with clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-containing chemotherapy. Using Affymetrix HU133A microarrays, we analyzed the lymphoma transcriptional profile of 30 patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and 23 patients treated with rituximab (R)-CHOP in the Groupe d'Etude des Lymphomes de l'Adulte clinical centers. We used this data set to select tra  ...[more]

Similar Datasets

| S-EPMC7394278 | biostudies-literature
| S-EPMC3208281 | biostudies-literature
| S-EPMC6366826 | biostudies-literature
| S-EPMC3668486 | biostudies-literature
| S-EPMC2424149 | biostudies-literature
| S-EPMC4467875 | biostudies-literature
| S-EPMC3952598 | biostudies-literature
| S-EPMC3496956 | biostudies-literature
| S-EPMC7970687 | biostudies-literature